Elizabeth Swisher Discusses Rucaparib's Side Effects for Patients With Ovarian Cancer

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.
ELIZABETH SWISHER, M.D.
PUBLISHED: MARCH 12, 2017
Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.


Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.

While overall deemed to be well-tolerated, the most common side effects that were experienced by patients were nausea, vomiting, fatigue, and anemia. These side effects get significantly better over the course of treatment.

Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.
x-button
Special Feature
Share Your Art
ONS Awards 2017
 
Cure Connections
x